J
Jeremy Swann
Researcher at Peter MacCallum Cancer Centre
Publications - 25
Citations - 5701
Jeremy Swann is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 16, co-authored 20 publications receiving 5239 citations. Previous affiliations of Jeremy Swann include University of Melbourne.
Papers
More filters
Journal ArticleDOI
Immune surveillance of tumors.
Jeremy Swann,Mark J. Smyth +1 more
TL;DR: This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments.
Journal ArticleDOI
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel,William Vermi,William Vermi,Jeremy Swann,Jeremy Swann,Nadeen Zerafa,Scott J. Rodig,Lloyd Old,Mark J. Smyth,Mark J. Smyth,Robert D. Schreiber +10 more
TL;DR: It is demonstrated that equilibrium occurs, is mechanistically distinguishable from elimination and escape, and that neoplastic cells in equilibrium are transformed but proliferate poorly in vivo, and it is shown that tumour cells inilibrium are unedited but become edited when they spontaneously escape immune control and grow into clinically apparent tumours.
Journal ArticleDOI
A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency
Carl R. Walkley,Gemma Haines Olsen,Sebastian Dworkin,Stewart A. Fabb,Jeremy Swann,Grant A. McArthur,Grant A. McArthur,Susan V. Westmoreland,Pierre Chambon,David T. Scadden,Louise E. Purton,Louise E. Purton +11 more
TL;DR: Data show that loss of RARgamma results in a nonhematopoietic cell-intrinsic MPS, revealing the capability of the microenvironment to be the sole cause of hematopOietic disorders.
Journal ArticleDOI
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Mark J. Smyth,Michele W.L. Teng,Jeremy Swann,Konstantinos Kyparissoudis,Dale I. Godfrey,Yoshihiro Hayakawa +5 more
TL;DR: CD4+CD25+ regulatory T cells (Treg) directly inhibit NKG2D-mediated NK cell cytotoxicity in vitro and in vivo, effectively suppressing NK cell-mediated tumor rejection.
Journal ArticleDOI
NKG2D function protects the host from tumor initiation
TL;DR: It is shown that neutralization of NKG2D enhances the sensitivity of wild-type (WT) C57BL/6 and BALB/c mice to methylcholanthrene (MCA)-induced fibrosarcoma, and suggests an important early role for the NKG1D in controlling and shaping tumor formation.